← ANALYST RATINGS · TIPRANKS

National Research (NRC): analyst forecast and price target

$20.15 −4.55% close 16.10.26 · market cap $452M · Healthcare · Medical - Healthcare Information Services IWM 0.01%
Price targets and ratings of

Analyst consensus

Moderate Buy

1 Buy0 Hold0 Sell

Ratings of 1 analysts in the last 3 months

12-month forecast

$26.00+29.0% upside

Based on 1 price targets given in the last 3 months, the average target is $26.00, the highest $26.00, the lowest $26.00. The average is +29.0% from the last price of $20.15.

$15.00$20.00$25.00Jan 26AprJulOctJan 27AprJulOctHigh$26.00Average$26.00Low$26.00
Highest target $26.00 Average target $26.00 Lowest target $26.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Constantine Davides★★★★★★★★★★#12158 · hits 36% · avg −12.7% Citizens JMP $23.00 → $26.00+13.0% Buy +29.0% Reiterated 29.07.26on TipRanks 05:51 −16.5%next day +1.7% · 5 days +1.2%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering National Research

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%
1 year Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%
2 years Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%

Most profitable

3 months Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%
1 year Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%
2 years Constantine Davides★★★★★★★★★★Citizens JMP · #12158
Hits 36%51 of 140 Average return −12.7%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $26.00 at a price of $21.19 (+22.7%); now: $26.00 at $20.15 (+29.0%).

$20.00$22.00$24.00$26.00Sep 15Oct 1Oct 15Average target$26.00Price$20.15

PriceAverage targetTop analysts’ target

Recommendation trend

00112Oct 25NovDecJan 26FebMarAprMay1Jun2Jul2Aug1SepOct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy012210
Hold000000
Sell000000

Earnings and sales forecast

Next report: 03.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.21 (from $0.21 to $0.21). Last quarter: $0.31.

Sales

Next quarter’s sales estimate — $36M (from $36M to $36M). Last quarter: $35M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About National Research
  • CEO: Trent Green
  • Employees: 357
  • 1245 Q Street, Lincoln, NE, 68508, US
  • nrchealth.com

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

Data from the stock’s TipRanks forecast page, read 109 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗